R&D News | pharmaphorum

News

Pathos AI's big $365m Series D, and other bio financings

Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.

News

Datavant, Aetion merger creates real-world data force

Datavant and Aetion merger promises "faster, more actionable" real-world data insights across pharma's clinical and commercial lifecycle.

News

Sanofi pledges a $20 billion investment programme in the US

Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.

News

RFK Jr defends HHS cuts, measles stance in Congress hearings

HHS Secretary Robert F Kennedy Jr would not explicitly endorse measles vaccines at Congressional hearings, and deflected questions on department cuts.

News

Novo makes fresh obesity play with $2.2bn Septerna deal

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.

News

GSK pays $1.2bn for liver drug as it culls TIGIT programme

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

Pathos AI's big $365m Series D, and other bio financings

Datavant, Aetion merger creates real-world data force

Sanofi pledges a $20 billion investment programme in the US

RFK Jr defends HHS cuts, measles stance in Congress hearings

Novo makes fresh obesity play with $2.2bn Septerna deal

GSK pays $1.2bn for liver drug as it culls TIGIT programme

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks